International Journal of Medical Reviews

International Journal of Medical Reviews

Green Synthesis of Silver Nanoparticles from Glycine max Pods: Potential Anti-Cancer Activity Against Hepatocellular Carcinoma

Document Type : Original Article

Authors
1 Department of Chemistry, University of Engineering and Technology, Lahore,54890, Pakistan
2 Department of Plant Pathology, University of the Punjab, Lahore, 54000, Pakistan
3 Department of Biochemistry & Molecular Biology, University of Gujrat,50700, Pakistan
4 School of Chemistry, University of Punjab, Quiad-e-Azam Campus, Lahore, 54000, Punjab, Pakistan
5 Center of Pharmaceutical Engineering Science, Faculty of Life Science, School of Pharmacy, University of Bradford, BD7 1DP, UK
6 Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. BOX 2457; Riyadh 11451, Saudi Arabia
Abstract
Introduction: Hepatocellular carcinoma, represents one of the greatest burdens in the oncology domain, with a significant negative global health and mortality rates. Glycine max, a plant used for centuries in various traditional medicine approaches, has shown good anti-cancer potential. The main objective of study was to analyse the anti-cancer activity of nanoparticle of Glycine max .
Methods: Nanoparticles were synthesized with Glycine max pods extract and a silver nitrate aqueous solution. Moreover, these are characterized via SEM-EDX, UV, XRD, and DLS analysis. Cell viability and cytotoxicity of bioinspired AgNPs was accessed using MTT as well as the trypan blue assay.
Results: Structural alterations of HepG2 cells were analysed by phase contrast microscope, showing significant results at a dose of 30 μg/ml. The upregulated expression of Annexin-V protein confirms that cell death occurred through apoptosis .
Conclusion: Glycine max has demonstrated its capability to produce AgNPs with apoptotic activities in vitro, offering a promising and economical solution for potentially combating hepatocellular carcinoma.
Keywords

Volume 11, Issue 4
Autumn 2024
Pages 830-841

  • Receive Date 01 January 2025
  • Revise Date 24 January 2025
  • Accept Date 27 January 2025